Lionco Pharmaceutical GroupLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Ling Ping Tao
Chief executive officer
CN¥660.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 6.8% |
| Management average tenure | no data |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Jan 02
Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%
Nov 06Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?
Oct 29Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
May 10There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump
Mar 12CEO
Ling Ping Tao (54 yo)
Ms. Ling Ping Tao is General Manager of Lionco Pharmaceutical Group Co.,Ltd. and serves as its Chairman of the Board.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | no data | CN¥660.00k | 6.84% CN¥ 236.9m | |
| Deputy GM | no data | CN¥900.00k | 2.29% CN¥ 79.4m | |
| Independent Director | 6.3yrs | CN¥120.00k | no data | |
| Independent Director | 6.3yrs | CN¥120.00k | no data | |
| Independent Director | 3.2yrs | CN¥120.00k | no data | |
| Director | 3.2yrs | no data | no data | |
| Member of Supervisory Board | no data | no data | no data |
Experienced Board: 603669's board of directors are considered experienced (4.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 12:43 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lionco Pharmaceutical Group Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.